50 results about "Psilocin" patented technology

The present disclosure provides methods of manufacturing psilocybin and crystalline psilocybin via a reaction of psilocin and tetrabenzylpyrophosphate in the presence of lithium chloride complex Grignard reagent, which is followed by hydrogenation. Methods of producing psilocin from 4-hydroxyindole or 4-acetoxyindole are also provided.

The present disclosure relates to pharmaceutical compositions formulated with psilocin and / or deuterated psilocin compounds or pharmaceutically acceptable salts, polymorphs, stereoisomers, or solvates thereof, and an organic acid agent as a pharmaceutically acceptable vehicle. Uses in the treatment of diseases, such as those associated, with a 5-HT2 receptor, are also disclosed.

The invention relates to a co-crystal or salt comprising psilocin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.

The present disclosure provides a method of treating or ameliorating a mental health disorder or a central nervous system disorder in a subject in need thereof, comprising administering to the subject a composition comprising a crystalline form of psilocin and psilocybin, wherein the crystalline form is co-crystal form A of psilocin and psilocybin and an atypical antipsychotic.

The present application relates to cost-effective, practical and scalable synthetic routes for the syntheses for psilocybin (Formula I) and its major metabolite psilocybin (Formula II) and their pharmaceutically acceptable salts. These compounds are useful for the treatment or prevention of mental health disorders, such as major depressive disorder, anxiety and addiction disorders, among others CNS disorders.

There is provided a method of treating or alleviating at least one symptom of a gut–brain interaction (DGBI) disorder in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound selected from psilocin, psilocybin, a derivative thereof, a crystalline form thereof, a cocrystal thereof, and a pharmaceutically acceptable salt thereof. The methods may involve inducing a psychedelic state in the subject and providing psychological support to the subject.

The present disclosure provides a composition comprising crystalline forms A, B, and C of psilocin and psilocybin. Solvent screen, X-ray powder diffractogram, thermogravimetric mass spectroscopy, differential scanning calorimetry, 1H-NMR, dynamic vapor sorption, and UPLC data on each of the crystalline forms is presented, along with methods preparing each of the crystalline forms.

The invention features psilocin formulations for intravenous infusions including psilocin benzoate salt in combination with an antioxidant.

The present disclosure provides methods of manufacturing psilocybin and crystalline psilocybin via a reaction of psilocin and tetrabenzylpyrophosphate in the presence of lithium chloride complex Grignard reagent, which is followed by hydrogenation. Methods of producing psilocin from 4-hydroxyindole or 4-acetoxyindole are also provided.

Various aspects of this disclosure relate to methods to treat health conditions in human patients, comprising administering a therapeutically-effective dose of a neuroplastic agent. Various aspects of this disclosure relate to method to assimilate human patients to prosthetics, comprising administering a therapeutically-effective dose of a neuroplastic agent. In some embodiments, the neuroplastic agent is a tryptamine such as psilocybin or psilocin.

The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.

The present invention composition features pharmaceutically acceptable salts of psilocin and compositions thereof. The pharmaceutically acceptable salts of psilocin may be used to treat a disease or condition, such as a neurological injury, an inflammatory condition, chronic pain, or a psychological condition, in a subject in need thereof.

The present disclosure provides a method of treating or ameliorating a disease or disorder in a subject in need thereof, comprising administering to the subject a composition comprising a crystalline form of psilocin and psilocybin, wherein the crystalline form is co-crystal form A of psilocin and psilocybin. The disclosure further provides methods of stimulating inducing neuroplasticity, increasing BDNF levels, and / or decreasing neuroinflammation.

Various aspects of this disclosure relate to the discoveries that (1) acids can catalyze the spontaneous dephosphorylation of phosphoryloxytryptamines into hydroxytryptamines such as psilocybin into psilocin, and (2) hydroxytryptamines are less stable to spontaneous oxidation than phosphoryloxytryptamines. The salt of a phosphoryloxytryptamine and an anion that is the conjugate base of a weak acid can buffer pH upon dissolution of the salt to inhibit the acid-catalyzed dephosphorylation of the phosphoryloxytryptamine and thereby protect it from spontaneous oxidation. Suitable anions include acetate, bicarbonate, dihydrogen phosphate, aspartate, and glutamate.

The invention features psilocin formulations for intravenous infusions including psilocin benzoate salt in combination with an antioxidant.

A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual, and treating the disease or condition.

The present invention relates to crystalline forms of psilocin (4-hydroxy-N,N-dimethyltryptamine) salts or cocrystals, as well as compositions, methods of preparation and methods of their use. The present invention also relates to said crystalline forms having improved physical properties such as aqueous solubility and stability, wherein the crystalline forms and compositions thereof are suitable for oral, subcutaneous, intravenous, or intramuscular administration.

A composition of psilocin that is stable including at least one agent or chemical modification that provides enhanced stability. A method making stable psilocin, by providing a formulation of psilocin including at least one agent or chemical modification that provides enhanced stability. A method of treatment of a disease or condition, by administering a composition of psilocin that is stable to an individual and treating the disease or condition.

This disclosure relates to heterocyclic compounds of Formula (I) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I) can be any one of a carbohydrate conjugate and an amino acid conjugate. The heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

Provided are improved methods for treating a psychological disorder in a subject comprising administering to the subject an amount of psilocybin or psilocin sufficient to induce a dissociative state in the subject less than 30 minutes after the administration; and thereafter maintaining the mean plasma concentration of the psychedelic at a predetermined value to maintain the dissociative state during a therapeutic window.

The invention relates to the technical field of emergency detection, in particular to a method for detecting dephosphorylated nummulina velutipes and toad tryptamine in a urine sample. According to the method, a to-be-detected urine sample is detected by adopting an Online SPE-LC-MS / MS method, a liquid chromatographic column is a BEHC18 chromatographic column, and a solid-phase extraction column is an online HLB small column. According to the method, online purification and enrichment of the sample can be automatically completed, the analysis time is short, the requirement for the dosage of the urine sample is small, complex sample pretreatment is not needed, the detection limit can reach 0.03 ng / mL, and the method has good sensitivity and accuracy and can meet the analysis requirement of the actual sample. The method is of great significance to identification of food poisoning sources and symptomatic treatment of patients.

The present disclosure provides methods of therapy using psilocybin or psilocin pegylated derivatives for the treatment of prediabetes, type-II diabetes, obesity, metabolic dysfunction-associated steatotic liver disease (MASLD and MetALD), metabolic dysfunction-associated steatohepatitis (MASH), non-alcoholic fatty liver disease (NAFLD), liver steatosis, dyslipidemia, nonalcoholic steatohepatitis (NASH), or sarcopenia.

The present disclosure provides a method of treating or ameliorating a mental health disorder or a central nervous system disorder in a subject in need thereof, comprising administering to the subject a composition comprising a crystalline form of psilocin and psilocybin, wherein the crystalline form is co-crystal form A of psilocin and psilocybin and an atypical antipsychotic.